Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029146 | 0.79 | HCAR3 (0.37) | POLBGPR55CHRM2CHRM4SMN1; SMN2 | |
| SCHEMBL19850785 | 0.79 | HCAR3 (0.37) | POLBGPR55CHRM2CHRM4SMN1; SMN2 | |
| SCHEMBL6589887 | 0.76 | MAPK1 (0.34) | POLBGPR55CHRM2CHRM4SMN1; SMN2 | |
| SCHEMBL1993661 | 0.76 | MAPK1 (0.34) | POLBGPR55CHRM2CHRM4SMN1; SMN2 | |
| SCHEMBL2795267 | 0.75 | MAPK1 (0.33) | POLBGPR55SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL7680574 | 0.75 | MAPK1 (0.33) | POLBGPR55SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL10029114 | 0.74 | EGFR (0.33) | CHRM2CHRM4SMN1; SMN2MAPK1USP2 | |
| SCHEMBL10557372 | 0.73 | L3MBTL1 (0.40) | CHRM2CHRM4SMN1; SMN2MAPK1USP2 | |
| SCHEMBL10553064 | 0.73 | L3MBTL1 (0.40) | CHRM2CHRM4SMN1; SMN2MAPK1USP2 | |
| SCHEMBL19839514 | 0.72 | L3MBTL1 (0.43) | CHRM2CHRM4SMN1; SMN2MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906871-B2 | Processes for making, and methods of using, glycopyrronium compounds | DERMIRA, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190161443-A1 | PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS | SWK FUNDING LLC | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906871-B2 | Processes for making, and methods of using, glycopyrronium compounds | GYPA, TPO, CYP21A2 | POLB 2132/4885GPR55 944/4885CHRM2 735/4885 |
| US-20190161443-A1 | PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS | GYPA, TPO, CYP21A2 | POLB 2132/4885GPR55 944/4885CHRM2 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.